LEO Pharma Selects Aris Global’s Register™ for Regulatory Affairs Management
CHICAGO & BALLERUP, Denmark–(BUSINESS WIRE)–DIA ANNUAL CONFERENCE—Aris Global, a leading provider of software solutions for the life sciences industry and LEO Pharma, a global, independent, research-based pharmaceutical company, today announced that LEO Pharma will deploy Aris Global’s Register as its integrated Regulatory Affairs management system. Using Register, LEO Pharma expects that authorized users will be able to track and monitor the drug product, country- and company-specific registration data at the global and/or at the local level with much greater ease and confidence.
Used by a number of top pharmaceutical companies across the world, Register is a market-leading solution for managing products and tracking global registrations and post-approval activities across each product’s entire lifecycle. It ensures that organizations have a single, integrated regulatory submission system that can automate and establish full control of all Regulatory Affairs activities worldwide.
“This strategic project is of great importance to LEO Pharma to enable Regulatory Affairs to share information and plans in our global organisation and with our internal stakeholders. We expect to increase oversight and efficiency, and create a platform that enables us to effectively comply with changes in regulatory requirements,” said Nina Christiansen, Director, Corporate Regulatory Affairs, LEO Pharma.
“We are excited to embark on this journey with LEO Pharma,” said Wim Cypers, Vice President, Regulatory Affairs, Aris Global. “Regulatory Affairs activities are not simply about document submissions. There’s an elaborate process that tracks end-to-end registration activities. With Register, LEO Pharma will have the best-in-class system to manage that process in the most efficient and cost effective manner.”
About LEO Pharma
Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company based in Ballerup near Copenhagen, Denmark. LEO Pharma is wholly owned by the LEO Foundation and is one of the world’s leading companies within the treatment areas of dermatology (psoriasis, skin infections and eczema) as well as prevention and treatment of thrombosis. A number of new products are being developed e.g. for treatment of the skin disorder actinic keratosis (initial stages of skin cancer caused by sun damage).
LEO Pharma develops, manufactures and markets competitive and safe drugs globally. 96% of the group’s turnover is generated outside Denmark, where LEO Pharma’s products are sold in more than 100 countries. LEO Pharma has its own sales forces in 58 countries and employs more than 3,900 full-time employees worldwide, of whom approximately 1,400 work in Denmark.
About Aris Global
Aris Global is a leading provider of integrated software solutions for pharmacovigilance and safety, regulatory affairs, clinical research and medical information. More than 150 life science organizations rely on the company’s advanced solutions for maintaining regulatory compliance, managing and mitigating risk, improving operational efficiency and easily sharing information on a global basis. Aris Global has headquarters in Stamford, CT, USA and regional offices in the UK, France, Germany, India, Italy and Japan offering sales, implementation and support services.
